Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949768 | 0.82 | GPR84 (0.47) | GPR84MEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL13978021 | 0.73 | GPR84 (0.48) | GPR84PTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL14877441 | 0.73 | GPR84 (0.44) | GPR84MEN1KMT2ACYP3A4ADORA3 | |
| SCHEMBL254525 | 0.73 | GPR84 (0.44) | GPR84MEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL10815973 | 0.72 | MEN1 (0.37) | GPR84MEN1KMT2APTGS2CYP3A4 | |
| SCHEMBL92739 | 0.69 | KCNH2 (0.46) | GPR84MEN1KMT2APTGS2CYP3A4 | |
| SCHEMBL8039222 | 0.69 | PTGS2 (0.40) | GPR84PTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL29168795 | 0.69 | PTGS2 (0.40) | GPR84PTGS2CYP3A4ESR1ADRA2A | |
| SCHEMBL28762822 | 0.69 | GABRP (0.37) | GPR84MEN1KMT2APTGS2CYP3A4 | |
| SCHEMBL3661591 | 0.68 | GPR84 (0.46) | GPR84CYP3A4ADORA3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700601-B2 | Substituted indazoles of formula 1.0 that are kinase inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1871765-B1 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | GPR84 1643/4885MEN1 1654/4885KMT2A 1233/4885 |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | BRCA1, PDK2, PDK1 | GPR84 1890/4885MEN1 1790/4885KMT2A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.